Glenmark to launch Lobeglitazone in India for T2 diabetes in adults

Glenmark Pharmaceuticals Limited has become the first to launch Thiazolidinedione Lobeglitazone in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG, it contains lobeglitazone (0.5 mg) and is to be taken once daily under prescription to improve glycaemic control in adult diabetic patients. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled type 2 diabetes among insulin‐resistant diabetic patients, the statement said.

Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing lobeglitazone based on a randomised, double‐blind Phase 3 clinical trial conducted on adult type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycaemic control with lobeglitazone.